Ticlopidine as a Hemorrhagic Risk Factor in Coronary Surgery
- 1 September 1985
- journal article
- research article
- Published by SAGE Publications in Drug Intelligence & Clinical Pharmacy
- Vol. 19 (9) , 673-676
- https://doi.org/10.1177/106002808501900912
Abstract
We retrospectively reviewed the postoperative hemorrhagic risk in patients undergoing surgery for coronary revascularization who had received platelet antiaggregants preoperatively. A significant increase in postoperative hemorrhage and a higher percentage of reoperations for this reason was observed in the patients treated with ticlopidine. However, there were no major differences in the platelet counts among the groups compared.Keywords
This publication has 17 references indexed in Scilit:
- Effect of Dipyridamole and Aspirin on Late Vein-Graft Patency after Coronary Bypass OperationsNew England Journal of Medicine, 1984
- Ticlopidine hydrochloride: Relationship between dose, kinetics, plasma concentration and effect on platelet functionThrombosis Research, 1983
- EFFECTS OF PLATELET INHIBITION ON MYOCARDIAL ISCHAEMIAThe Lancet, 1982
- A Platelet-Inhibitor-Drug Trial in Coronary-Artery Bypass OperationsNew England Journal of Medicine, 1982
- Aspirin inhibits platelet function independent of the acetylation of ciclo-oxygenaseThrombosis Research, 1982
- Antithrombotic therapy with ticlopidine in chronic renal failure patients on maintenance hemodialysis -a multicenter collaborative double blind study-Thrombosis Research, 1980
- SulfinpyrazoneDrugs, 1980
- Compared effects of three dose-levels of ticlopidine on platelet function in normal subjectsThrombosis Research, 1979
- The effect of ticlopidine on platelet function in normal volunteers and in patients with platelet hyperaggregabilityThrombosis Research, 1979
- Ticlopidine - An antiplatelet drug: Effects in human volunteersThrombosis Research, 1978